Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

Completed

Conditions studied: Lung Cancer, Colorectal Cancer, Head and Neck Cancer

In brief

The purpose of this study is to look at several genes that might determine how the body processes the drugs used to treat lung, colorectal and head and neck cancers. The goal of this examination is to help investigators determine the proper dosage to give future cancer patients or to better predict which future patients will respond to particular drug therapies.

Key facts

Study ID

NCT00442520

Run by

University of Kansas Medical Center

People needed

70

Starts

2006-02-01

Expected to finish

2008-09-01

Last updated by the study team

2016-11-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Lung, Colorectal and Head and Neck Cancer Patients that have received or plan to receive chemotherapy as part of their treatment

You may not qualify if…

• Colorectal cancer patients that have never received or will not receive chemotherapy as part of their therapy
• Head and Neck cancer patients that have never received or will not receive chemotherapy as part of their treatment
• Patients with cancer types other than colorectal or head and neck
• Unable to give informed consent

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.